Skip to main content

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

2022 Special Issues: Open for Submission

Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments

This special issue published by Molecular Cancer focuses on the clinical aspects of liquid biopsies, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' risks of disease progression and response to specific therapies.


Open for submission. Submission window closes 15th November 2021.

Genome Editing and the Future of Personalized and Targeted Cancer Medicine

Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.


Open for submission. Submission window closes 15th November 2021.

Editor-in-Chief

Christophe Nicot, Kansas University Medical Center, USA

Aims and scope

Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.

Read more

Articles

  1. Authors: Mathias Dahlmann, Guido Gambara, Bernadette Brzezicha, Oliver Popp, Eva Pachmayr, Lena Wedeken, Alina Pflaume, Margarita Mokritzkij, Safak Gül-Klein, Andreas Brandl, Caroline Schweiger-Eisbacher, Philipp Mertins, Jens Hoffmann, Ulrich Keilholz, Wolfgang Walther, Christian Regenbrecht…

    Content type: Letter to the Editor

  2. Authors: Atish Kizhakeyil, Nurmahirah Binte Mohammed Zaini, Zhi Sheng Poh, Brandon Han Siang Wong, Xinpeng Loh, Aik Seng Ng, Zun Siong Low, Praseetha Prasannan, Chun Gong, Michelle Guet Khim Tan, Chandramouli Nagarajan, Dachuan Huang, Pang Wan Lu, Jing Quan Lim, Sharon Barrans, Choon Kiat Ong…

    Content type: Letter to the Editor

2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer

2021 SI imageMolecular Cancer is delighted to announce the new thematic series entitled 'mRNA therapies and mRNA vaccines in cancer.'

Click here to view this collection.

Click here to access all thematic series published to date in Molecular Cancer.

Featured Article: Role of the NLRP3 inflammasome in cancer

In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.


CAHON: Stop hate crimes and racism

The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond. 

Recognising Editorial Excellence

Editorial Excellence BadgeMolecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

What is trending?

Altmetric doughnutClick here to see which articles published in Molecular Cancer have been shared the most in the past three months.

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Annual Journal Metrics